{
    "2018-02-11": [
        [
            {
                "time": "",
                "original_text": "医药生物行业周报：机会可以是跌出来的",
                "features": {
                    "keywords": [
                        "医药",
                        "生物",
                        "行业周报",
                        "机会",
                        "跌出来"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-02",
                "original_text": "[买入评级]2018年2月份医药行业投资策略：医药板块中期走强趋势不变，迎战略性加仓机会",
                "features": {
                    "keywords": [
                        "买入评级",
                        "医药",
                        "投资策略",
                        "中期走强",
                        "加仓机会"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[买入评级]长春高新(000661)年报点评：生长激素引领业绩高增长，龙头地位持续稳固",
                "features": {
                    "keywords": [
                        "买入评级",
                        "长春高新",
                        "年报",
                        "生长激素",
                        "业绩高增长",
                        "龙头地位"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2017",
                "original_text": "【华创医药】长春高新(000661.SZ)2017年年报点评：生物类药品快速增长，业绩符合预期",
                "features": {
                    "keywords": [
                        "华创医药",
                        "长春高新",
                        "年报",
                        "生物类药品",
                        "快速增长",
                        "业绩符合预期"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}